Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Original title: “HR 9990: Increasing Mental Health Options Act of 2026”

The Food and Drug Administration (FDA or we) is announcing the fiscal year (FY) 2027 annual fee rate for recognized accreditation bodies and accredited certification bodies, and the initial and renewal fee rate for accreditation bodies applying to be recognized in the third-party certification program authorized by the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the FDA Food Safety Modernization Act (FSMA). We are also announcing the fee rate for certification bodies applying

Original title: “Food Safety Modernization Act Third-Party Certification Program User Fee Rate for Fiscal Year 2027”

ACF/OHS announces its intent to award multiple single-source grants totaling $143,436,162 to select organizations operating a Head Start grant in Florida, South Carolina, and Puerto Rico who demonstrated Head Start services in the affective areas were either disrupted or impacted by Hurricanes Fiona and Ian. These awards are for necessary expenses directly related to the consequences of Hurricanes Fiona and Ian, including replacement of damaged or destroyed property and facilities, and increased

Original title: “Announcement of the Intent To Award Single-Source Grants (Multiple Recipients) for Necessary Expenses Directly Related to the Consequences of Hurricanes Fiona and Ian”

The Food and Drug Administration (FDA, the Agency, or we) is announcing the fee rates and payment procedures for fiscal year (FY) 2027 generic new animal drug program user fees. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Animal Generic Drug User Fee Amendments of 2023 (AGDUFA IV), authorizes FDA to collect user fees for certain abbreviated applications for generic new animal drugs, for certain generic new animal drug products, for certain sponsors of such abbreviated

Original title: “Animal Generic Drug User Fee Program Rates and Payment Procedures for Fiscal Year 2027”

The Food and Drug Administration (FDA or we) is announcing the fiscal year (FY) 2027 rates for the establishment and reinspection fees related to entities that compound human drugs and elect to register as outsourcing facilities under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The FD&C Act authorizes FDA to assess and collect an annual establishment fee from outsourcing facilities, as well as a reinspection fee for each reinspection of an outsourcing facility. This document establishes

Original title: “Outsourcing Facility Fee Rates for Fiscal Year 2027”

Read twice and referred to the Committee on Veterans' Affairs.

Original title: “S 5177: New Mexico Rural Veteran Health Care Access Act”

The Federal Food, Drug, and Cosmetic Act (FD&C Act or statute), as amended by the Generic Drug User Fee Amendments of 2022 (GDUFA III), authorizes the Food and Drug Administration (FDA, Agency, or we) to assess and collect fees for abbreviated new drug applications (ANDAs); drug master files (DMFs); generic drug active pharmaceutical ingredient (API) facilities, finished dosage form (FDF) facilities, and contract manufacturing organization (CMO) facilities; and generic drug applicant program use

Original title: “Generic Drug User Fee Rates for Fiscal Year 2027”

The Food and Drug Administration (FDA, Agency, or we) is announcing the rates for biosimilar user fees for fiscal year (FY) 2027. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Biosimilar User Fee Amendments of 2022 (BsUFA III), authorizes FDA to assess and collect user fees for certain activities in connection with biosimilar biological product development; review of certain applications for approval of biosimilar biological products; and each biosimilar biological produ

Original title: “Biosimilar User Fee Rates for Fiscal Year 2027”

The Food and Drug Administration (FDA, Agency, or we) is announcing the fee rates and payment procedures for medical device user fees for fiscal year (FY) 2027. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Medical Device User Fee Amendments of 2022 (MDUFA V), authorizes FDA to collect user fees for certain medical device submissions and annual fees both for certain periodic reports and for establishments subject to registration. This notice establishes the fee rates for

Original title: “Medical Device User Fee Rates for Fiscal Year 2027”

This document withdraws a proposed rule that was published in the Federal Register on January 31, 2005. The proposed rule would have amended the regulations for Child and Family Services with respect to title IV-E administrative costs and eligibility determinations and re- determinations for title IV-E foster care recipients and foster care "candidates" to implement title IV-E foster care eligibility and administrative cost provisions in sections 472 and 474 of the Social Security Act (the Act)

Original title: “Administrative Costs for Children in Title IV-E Foster Care”

The Food and Drug Administration (FDA or we) is announcing the fiscal year (FY) 2027 annual fee rate for importers approved to participate in the Voluntary Qualified Importer Program (VQIP) that is authorized by the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the FDA Food Safety Modernization Act (FSMA). This fee is effective on August 1, 2026, and will remain in effect through September 30, 2027.

Original title: “Food Safety Modernization Act Voluntary Qualified Importer Program User Fee Rate for Fiscal Year 2027”

The Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS), Classifications and Public Health Data Standards Staff, announces the following meeting of the ICD-10 Coordination and Maintenance (C&M) Committee. This meeting is open to the public, limited only by the number of audio lines available. Online registration is required.

Original title: “National Center for Health Statistics, Meeting of the ICD-10 Coordination and Maintenance Committee”

The Food and Drug Administration (FDA or we) is reopening the comment period for the notice titled "Butylated Hydroxytoluene (BHT); Request for Information," which published in the Federal Register of May 13, 2026. We are taking this action in response to a request from stakeholders to extend the comment period to allow additional time for interested parties to develop and submit data, other information, and comments for this request for information.

Original title: “Butylated Hydroxytoluene (BHT); Request for Information; Reopening of Comment Period”

Referred to the House Committee on Energy and Commerce.

Original title: “HR 9833: Ensuring Kids Have Access to Medically Necessary Dental Care Act”

The Food and Drug Administration (FDA or Agency) is announcing the availability of additional revised draft product-specific guidances. The draft guidances provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). In the Federal Register of June 11, 2010, FDA announced the availability of a guidance for industry entitled "Bioequivalence Recommendations for Specific Products" that explained the

Original title: “Product-Specific Guidances; Revised Draft Guidances for Industry; Availability”

The Food and Drug Administration's (FDA) plans to centralize and enhance key functions across the agency. These changes will reduce redundancies, improve efficiency, and advance alignment to better serve the American public.

Original title: “Statement of Organization, Functions, and Delegations of Authority”

The Food and Drug Administration (FDA) is classifying the phase-changing fiducial marker for radiation therapy into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the phase-changing fiducial marker for radiation therapy. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiv

Original title: “Medical Devices; Radiology Devices; Classification of the Phase-Changing Fiducial Marker for Radiation Therapy”

The Diabetes Mellitus Interagency Coordinating Committee (DMICC) will hold a meeting on September 18th, 2026. The topic for this meeting will be "Type 1 Diabetes and Cardiorenal Outcomes: Informing a Practice Changing Trial".

Original title: “Notice of Diabetes Mellitus Interagency Coordinating Committee Meeting”